Navigation Links
BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations
Date:12/1/2008

COLUMBIA, S.C., Dec. 1 /PRNewswire-FirstCall/ -- Collexis Holdings, Inc. (OTC Bulletin Board: CLXS), a leading developer of semantic search and knowledge discovery software, announced today a partnership with BioFlorida, Inc., Florida's statewide bioscience association, to promote BiomedExperts.com to the association's 200+ membership base. Through the partnership, BiomedExperts.com will serve as the primary professional network for BioFlorida, helping to facilitate collaboration and advance scientific discovery among its member researchers.

BiomedExperts.com is the world's first literature-based professional social networking site that was pre-populated with more than 1.8 million expert profiles from PUBMED. The site allows scientists and researchers to directly connect with and explore their professional contacts, grow their networks and identify researchers with the expertise needed for future collaborations. With 60,000+ registered users worldwide, BiomedExperts.com provides user-friendly interfaces through which research collaborators can share data and network with 1,800 organizations and institutions from 137 countries, totaling more than 21 million connections made through the site.

"Meeting the demands of Florida's ever-growing bioscience industry can be quite a challenge. Collexis' BiomedExperts.com will assist us in overcoming issues associated with those challenges," said Russell Allen, BioFlorida's president & CEO. "Choosing BiomedExperts.com as our primary professional network will allow us to introduce our membership to BiomedExperts.com ever growing community. The network will enable our members to track the latest research in life sciences, and connect with leading industry experts."

"We are excited about this partnership with BioFlorida and its selection of BiomedExperts.com to further enable collaboration among its members," said Collexis CEO Bill Kirkland. "Collexis' technology will be a valuable asset to the association and its overall mission. Working together with BioFlorida, we will leverage their members' expertise in all areas of the bioscience industry to help advance research throughout Florida and beyond."

About BioFlorida, Inc.

BioFlorida is Florida's statewide trade association for the bioscience industry providing advocacy, business development and communications services for more than 200 member companies. Our mission is to be the voice of the bioscience industry and the advocate for our member organizations-both large and small. Bringing knowledge and resources to Florida's bioscience community, BioFlorida supports the health, agricultural and energy sectors of biotechnology as well as the pharmaceutical and medical technology fields. For more information, visit bioflorida.com .

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com . Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit www.collexis.com .

Forward-Looking Statements

Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the company's collaboration with BioFlorida. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-KSB for the period ended June 30, 2008. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.


'/>"/>
SOURCE Collexis Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedTechIQ Selects TheBrain to Visualize Expansive Biointellingence Database and Connect the Dots Between Life Sciences, Medicine and Venture Capital
2. Commonwealth Care Alliance Selects Casenet To Unify Patient Information and Improve Care for Massachusetts Members
3. Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers
4. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
5. Battelle Selects Xie to Develop Biomarker Services
6. Array BioPharma Selects SciQuest to Automate Procurement and Enable Agile Drug Development
7. HealthEast Care System Selects Concuitys ClearContracts to Increase Contract Analysis and Negotiation Capabilities and Improve Revenue Cycle Management
8. Pathology Consultants, Inc. Selects PSA, LLC, a MED3OOO Company, as Their Business Partner
9. diaDexus Selects Fisher HealthCare to Sell New Automated PLAC(R) Test
10. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
11. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
Breaking Biology News(10 mins):